Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Financial considerations Under the terms of the agreement, AstraZeneca has received a payment of $178m from Cheplapharm. The Company may also receive future sales-contingent payments of up to $61m. The upfront payment will be reported in AstraZeneca’s financial statements within Other Operating Income & Expense in the fourth quarter of 2019.